Literature DB >> 16741253

Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation.

Persis J Amrolia1, Giada Muccioli-Casadei, Helen Huls, Stuart Adams, April Durett, Adrian Gee, Eric Yvon, Heidi Weiss, Mark Cobbold, H Bobby Gaspar, Cliona Rooney, Ingrid Kuehnle, Victor Ghetie, John Schindler, Robert Krance, Helen E Heslop, Paul Veys, Ellen Vitetta, Malcolm K Brenner.   

Abstract

Poor T lymphocyte reconstitution limits the use of haploidentical stem cell transplantation (SCT) because it results in a high mortality from viral infections. One approach to overcome this problem is to infuse donor T cells from which alloreactive lymphocytes have been selectively depleted, but the immunologic benefit of this approach is unknown. We have used an anti-CD25 immunotoxin to deplete alloreactive lymphocytes and have compared immune reconstitution after allodepleted donor T cells were infused at 2 dose levels into recipients of T-cell-depleted haploidentical SCT. Eight patients were treated at 10(4) cells/kg/dose, and 8 patients received 10(5) cells/kg/dose. Patients receiving 10(5) cells/kg/dose showed significantly improved T-cell recovery at 3, 4, and 5 months after SCT compared with those receiving 10(4) cells/kg/dose (P < .05). Accelerated T-cell recovery occurred as a result of expansion of the effector memory (CD45RA(-)CCR-7(-)) population (P < .05), suggesting that protective T-cell responses are likely to be long lived. T-cell-receptor signal joint excision circles (TRECs) were not detected in reconstituting T cells in dose-level 2 patients, indicating they are likely to be derived from the infused allodepleted cells. Spectratyping of the T cells at 4 months demonstrated a polyclonal Vbeta repertoire. Using tetramer and enzyme-linked immunospot (ELISPOT) assays, we have observed cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-specific responses in 4 of 6 evaluable patients at dose level 2 as early as 2 to 4 months after transplantation, whereas such responses were not observed until 6 to 12 months in dose-level 1 patients. The incidence of significant acute (2 of 16) and chronic graft-versus-host disease (GVHD; 2 of 15) was low. These data demonstrate that allodepleted donor T cells can be safely used to improve T-cell recovery after haploidentical SCT and may broaden the applicability of this approach.

Entities:  

Mesh:

Year:  2006        PMID: 16741253      PMCID: PMC1895537          DOI: 10.1182/blood-2006-02-001909

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  45 in total

1.  Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation.

Authors:  Scott R Solomon; Stephan Mielke; Bipin N Savani; Aldemar Montero; Laura Wisch; Richard Childs; Nancy Hensel; John Schindler; Victor Ghetie; Susan F Leitman; Thao Mai; Charles S Carter; Roger Kurlander; Elizabeth J Read; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants.

Authors:  I Volpi; K Perruccio; A Tosti; M Capanni; L Ruggeri; S Posati; F Aversa; A Tabilio; L Romani; M F Martelli; A Velardi
Journal:  Blood       Date:  2001-04-15       Impact factor: 22.113

3.  Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft.

Authors:  P Tiberghien; C Ferrand; B Lioure; N Milpied; R Angonin; E Deconinck; J M Certoux; E Robinet; P Saas; B Petracca; C Juttner; C W Reynolds; D L Longo; P Hervé; J Y Cahn
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

4.  Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.

Authors:  D Montagna; E Yvon; V Calcaterra; P Comoli; F Locatelli; R Maccario; A Fisher; M Cavazzana-Calvo
Journal:  Blood       Date:  1999-05-15       Impact factor: 22.113

5.  Failure of SCID-X1 gene therapy in older patients.

Authors:  Adrian J Thrasher; Salima Hacein-Bey-Abina; H Bobby Gaspar; Stephane Blanche; E Graham Davies; Kathryn Parsley; Kimberly Gilmour; Douglas King; Steven Howe; Joanna Sinclair; Christophe Hue; Frédérique Carlier; Christof von Kalle; Geneviève de Saint Basile; Françoise le Deist; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Blood       Date:  2005-02-01       Impact factor: 22.113

6.  Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia.

Authors:  F Dazzi; R M Szydlo; C Craddock; N C Cross; J Kaeda; A Chase; E Olavarria; F van Rhee; E Kanfer; J F Apperley; J M Goldman
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

7.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse.

Authors:  Franco Aversa; Adelmo Terenzi; Antonio Tabilio; Franca Falzetti; Alessandra Carotti; Stelvio Ballanti; Rita Felicini; Flavio Falcinelli; Andrea Velardi; Loredana Ruggeri; Teresa Aloisi; Jean Pierre Saab; Antonella Santucci; Katia Perruccio; Maria Paola Martelli; Cristina Mecucci; Yair Reisner; Massimo F Martelli
Journal:  J Clin Oncol       Date:  2005-03-07       Impact factor: 44.544

8.  Prediction of T-cell reconstitution by assessment of T-cell receptor excision circle before allogeneic hematopoietic stem cell transplantation in pediatric patients.

Authors:  Xiaohua Chen; Raymond Barfield; Ely Benaim; Wing Leung; James Knowles; Dawn Lawrence; Mario Otto; Sheila A Shurtleff; Geoffrey A M Neale; Frederick G Behm; Victoria Turner; Rupert Handgretinger
Journal:  Blood       Date:  2004-09-09       Impact factor: 22.113

9.  Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.

Authors:  T N Small; E B Papadopoulos; F Boulad; P Black; H Castro-Malaspina; B H Childs; N Collins; A Gillio; D George; A Jakubowski; G Heller; M Fazzari; N Kernan; S MacKinnon; P Szabolcs; J W Young; R J O'Reilly
Journal:  Blood       Date:  1999-01-15       Impact factor: 22.113

10.  Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.

Authors:  F Aversa; A Tabilio; A Velardi; I Cunningham; A Terenzi; F Falzetti; L Ruggeri; G Barbabietola; C Aristei; P Latini; Y Reisner; M F Martelli
Journal:  N Engl J Med       Date:  1998-10-22       Impact factor: 91.245

View more
  82 in total

1.  Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation.

Authors:  Sergio Rutella; Franco Locatelli
Journal:  Am J Transl Res       Date:  2011-09-10       Impact factor: 4.060

Review 2.  Emerging concepts in haematopoietic cell transplantation.

Authors:  Hao Wei Li; Megan Sykes
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

3.  Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience.

Authors:  Conrad Russell Cruz; Patrick J Hanley; Hao Liu; Vicky Torrano; Yu-Feng Lin; James A Arce; Stephen Gottschalk; Barbara Savoldo; Gianpietro Dotti; Chrystal U Louis; Ann M Leen; Adrian P Gee; Cliona M Rooney; Malcolm K Brenner; Catherine M Bollard; Helen E Heslop
Journal:  Cytotherapy       Date:  2010-10       Impact factor: 5.414

4.  Short-term cryopreservation of allogeneic stem cells for optimization of transplant conditions in children.

Authors:  Petra Sovinz; Wolfgang Schwinger; Herwig Lackner; Andrea Nebl; Sabine Sipurzynski; Christian Urban
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 5.  Progress in haploidentical stem cell transplantation.

Authors:  Ulas D Bayraktar; Richard E Champlin; Stefan O Ciurea
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-09       Impact factor: 5.742

6.  Activated MHC-mismatched T helper-1 lymphocyte infusion enhances GvL with limited GvHD.

Authors:  Y Zeng; J Stokes; S Hahn; E Hoffman; E Katsanis
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

7.  Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease.

Authors:  Stephan Mielke; Katayoun Rezvani; Bipin N Savani; Raquel Nunes; Agnes S M Yong; John Schindler; Roger Kurlander; Victor Ghetie; Elizabeth J Read; Scott R Solomon; Ellen S Vitetta; A John Barrett
Journal:  Blood       Date:  2007-05-03       Impact factor: 22.113

8.  Induction of alloanergy in human donor T cells without loss of pathogen or tumor immunity.

Authors:  Jeffrey K Davies; Dongin Yuk; Lee M Nadler; Eva C Guinan
Journal:  Transplantation       Date:  2008-09-27       Impact factor: 4.939

Review 9.  Use of CD137 to study the full repertoire of CD8+ T cells without the need to know epitope specificities.

Authors:  Matthias Wölfl; Jürgen Kuball; Matthias Eyrich; Paul G Schlegel; Philip D Greenberg
Journal:  Cytometry A       Date:  2008-11       Impact factor: 4.355

10.  Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.

Authors:  D A Rizzieri; P Dev; G D Long; C Gasparetto; K M Sullivan; Ml Horwitz; J Chute; N J Chao
Journal:  Bone Marrow Transplant       Date:  2008-10-13       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.